Amyris, Inc.

Amyris, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Amyris, Inc. is not a good value stock. Amyris, Inc. is not very popular among insiders. Amyris, Inc. is a mediocre stock to choose.
Log in to see more information.
Amyris, Inc. is an industrial biotechnology company, which engages in the provision of bioscience so...
AMRS Fundamental Data by TradingView

News

Amyris options imply 60.6% move in share price post-earnings
Amyris options imply 60.6% move in share price post-earnings

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy.\n more…

Why Amyris Stock Is Rocketing Higher
Why Amyris Stock Is Rocketing Higher

Benzinga Amyris, Inc. (NASDAQ: AMRS) shares are trading higher Friday as the stock rebounds following a steep selloff after the company announced it filed for\n more…

Amyris, Inc. (NASDAQ:AMRS) Given Consensus Recommendation of "Hold" by Brokerages
Amyris, Inc. (NASDAQ:AMRS) Given Consensus Recommendation of "Hold" by Brokerages

Ticker Report Shares of Amyris, Inc. (NASDAQ:AMRS Get Free Report) have received a consensus rating of Hold from the six brokerages that are presently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating on ...\n more…

Synthetic biology pioneer Amyris files for Chapter 11 bankruptcy protection
Synthetic biology pioneer Amyris files for Chapter 11 bankruptcy protection

Bizjournals.com - Health Care News The bankruptcy court filing exposes ongoing financial losses, job cuts and allegations of supply chain and accounting irregularities.\n more…

Biotech Company Amyris Files for Bankruptcy
Biotech Company Amyris Files for Bankruptcy

Yahoo! Finance: News Synthetic biotechnology company Amyris filed for Chapter 11 bankruptcy protection as it restructures, leading its share price to drop more than 70% in early trading Thursday.\n more…